Abstract. Nucleus accumbens-associated protein 1 (NAC1), a transcriptional co-regulator, is overexpressed in advanced prostate cancer. However, the NAC1-regulated transcriptome has not been completely explored. In the present study, the functional silencing of NAC1 blocked the migration of prostate cancer cells and suppress osteoclastogenesis. The present study also determined that NAC1 was overexpressed in the highly aggressive prostate cancer cell lines PC-3, DU-145 and LNCaP. NAC1 small interfering RNA treatment of DU-145 cells decreased cell migration, but interestingly had no significant effects on cell proliferation. Furthermore, microarray analysis showed that a group of genes may be associated with the development of prostate cancer after NAC1 knockdown, including interferon-β (IFNβ), which is reported to be involved in osteoclastogenesis, an important factor affecting bone metastasis. The mechanisms of NAC1 function were further explored by co-culture studies using PC-3 and RAW264.7 osteoclast precursor cells, which demonstrated that silencing NAC1 downregulated the genes associated with the activation of osteoclasts. Furthermore, it was revealed that NAC1 had the ability to affect the release of IFNβ into the extracellular environment. Together, these findings indicated that NAC1 promoted cell migration, and that NAC1 may have a key role in osteoclastogenesis.
Introduction
Prostate cancer is the second most frequently diagnosed cancer in men worldwide, and with an increasing incidence.
It is also the fifth leading cause of cancer-related death worldwide, and >250,000 men die of prostate cancer each year (1, 2) . In prostate cancer patients, bone is the most common site of distant metastasis, which is the predominant cause of morbidity and mortality. In addition, bone destruction can increase the risk of death by >20% in patients with bone metastasis (3, 4) . However, at present, few drugs are able to delay the skeletal events (such as bone destruction or pain caused by bone metastasis), and the available treatments for bone pain are unsatisfactory (5) . Therefore, the molecular mechanisms of bone metastasis from prostate cancer must be further explored, and more efficacious therapeutic targets are urgently required.
Nucleus accumbens-associated protein 1 (NAC1) belongs to a family of proteins with the Pox virus and zinc finger (POZ; also known as BTB) domain, a versatile protein-protein interaction motif in the N-terminus that mediates either homodimer or heterodimer formation (6) (7) (8) . Moreover, NAC1 is a transcriptional co-factor that participates in self-renewal and maintenance of pluripotency in embryonic stem cells (9, 10) . Recent studies have revealed that NAC1 is markedly up-regulated in several types of human carcinomas, and is involved in the proliferation, autophagy, senescence, chemotherapy resistance, cytokinesis, migration and motility of cancer cells (11) (12) (13) (14) (15) (16) ). An abundance of NAC1 protein seems to correlate with poorer prognosis in certain carcinomas in humans (17) . However, the explicit mechanism of NAC1 in prostate cancer has not yet been reported. Given the significant and diverse roles of NAC1 in cancer biology, the purpose of the present study was to investigate the role of NAC1 in the development of prostate cancer and bone metastasis. Colony formation assay. At 24 h after transfection, DU-145 cells (1.5x10 3 cells per well were plated in 6-well plates and incubated at 37˚C in a humidified atmosphere containing 5% CO 2 /95% air for 14 days to allow for the formation of colonies. The colonies were washed twice with PBS, and the cells were then stained with 0.1% crystal violet for 20 min and washed with water before the colonies (each ≥50 cells) were counted.
Materials and methods

Patients
Wound healing assay and Transwell assay. To study cell migration, DU-145 cells were cultured to confluence in 6-well plates, and a 2-mm-wide single, uninterrupted scratch in the cell layer was made across the diameter of each well. The culture plates were incubated with RPMI-1640 for 24 h and then washed with PBS, and photomicrographs were captured to assess the change in the size of the wound area. 
NAC1, Nuclear accumbens-associated protein 1; IFNβ, interferon-β; IL-24, interleukin 24; NFATc1, nuclear factor of activated T-cells cytoplasmic 1; S100A9, S100 calcium-binding protein A9; GAB1, GRB 2-associated binding protein 1; MMP9, matrix metalloproteinase 9; VEGFA, vascular endothelial growth factor A; RANK, receptor activator of NF-kB; GAPDH, Glyceraldehyde 3-Phosphate Dehydrogenase.
Transwell assays were also performed to quantify the migration of DU-145 cells. Uncoated inserts (cat. no. 354578; BD Biosciences, San Jose, CA, USA) were used for the migration assays. Duplicate wells were assessed. DU-145 cells were seeded on top of the inserts in RPMI-1640 and cultured for 24 h, after which the cells that had migrated to the underside of the membrane were visualized. Cells were counted in five individual fields on each insert.
Microarray analysis. DU-145 cells were transfected with the two NAC1 siRNAs or a negative control siRNA. At 48 h after transfection, the cells were harvested for microarray analysis. An Arraystar Human messenger RNA (mRNA) Microarray v3.0 was used and run by the service provider. The array contained 30,215 protein-coding transcripts. A specific exon or splice junction probe which could identify an individual transcript accurately was used to represent each transcript. Positive probes for housekeeping genes and negative probes were also included in the array for hybridization quality control. The microarray hybridization and bioinformatics analysis were performed by KangChen Bio-tech (Shanghai, China).
RT-qPCR. Total RNA was extracted from the cells with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. The relative expression levels of the mRNAs were determined by real-time RT-qPCR using a standard SYBR Green RT-PCR Kit (Takara Bio, Inc., Otsu, Japan). The specific primer pairs used in this study are listed in Table I . Averages of the Ct values from duplicate measurements were obtained. The relative expression levels of mRNAs were quantified using GraphPad Prism v5.0 software (GraphPad Software, Inc., San Diego, CA, USA) and the 2 -ΔΔCt method.
Co-culture studies. Boyden chambers (3-µm hole inserts; Corning Incorporated, Corning, NY, USA) were used to assess the influence of PC-3 cells on osteoclasts using RAW 264.7 mouse monocytes. RAW 264.7 cells (1x10 5 ) were plated in 6-well plates for 24 h, then PC-3 cells (1x10 5 ) transfected with NAC1 siRNA or negative control siRNA were added into the upper chamber. RPMI-1640 supplemented with 10% fetal bovine serum was used to culture the PC-3 cells and DMEM supplemented with 10% fetal bovine serum was used to culture the RAW264.7 cells. IFNβ concentrations were detected by ELISA of the co-culture medium (as described below), and osteoclast formation was evaluated by RT-qPCR and western blot analyses of the total RNA and protein extracted from RAW 264.7 cells after culturing for 72 h.
Enzyme-linked immunosorbent assay (ELISA).
The protein level of IFNβ in the conditioned medium was assessed using human immunoassay ELISA kits (CUSABIO, Wuhan, China). The optical densities were measured at 450 nm and the detection limits were set in accordance with the log-log correlative coefficient of the standard curve.
Statistical analysis. Data were expressed as the mean ± SEM. Student's t-test (for comparison between two groups) was used to evaluate the numeric data. The χ 2 test was used for comparisons of categorical data. A value of P<0.05 was considered to indicate a statistically significant difference. revealed that NAC1 expression was markedly higher in tumor tissues (Fig. 1A) (Fig. 1B-D and Table II ). It also revealed that the NAC1 immunoreactivity was closely related to the clinical stage of prostate cancer (P<0.05). However, there were no significant associations with patient age, preoperative prostate-specific antigen level or Gleason score (Table II) .
Results
NAC1 expression is up-regulated in the progression
Silencing NAC1 expression decreases the migratory ability of prostate cancer cells. Since NAC1 was up-regulated in prostate cancer at advanced clinical stages, we next assessed the biological function of NAC1 in prostate cancer cells. NAC1 was expressed in the highly aggressive prostate cancer cell lines PC-3, DU-145 and LNCaP ( Fig. 2A) . DU-145 cells, which have the highest degree of malignancy, were selected for further study. Two NAC1 siRNAs (designated siNAC1-1 and siNAC1-2) were transfected into the cells. Treatment with siNAC1-1 or siNAC1-2 significantly reduced NAC1 protein expression compared with that in DU-145 cells transfected with negative control siRNA (NC) (Fig. 2B) . However, siNAC1-1 and siNAC1-2 did not significantly reduce the numbers of DU145 cells compared with the NC group (Fig. 2C) . To confirm the result, a colony formation assay was performed, which revealed a slight but non-significant difference between the NAC1 siRNA and NC groups (Fig. 2D) .
Subsequently, we investigated whether NAC1 played a causal role in the migration characteristics of prostate cancer cells by employing a wound-healing assay. A wound was scratched on the surface of DU-145 cells transfected with siNAC1-1, siNAC1-2 or NC siRNA, and the width of the gap was measured after 24 h. The cells in the siNAC-1 and siNAC1-2 groups migrated less than those in the NC group, as shown in Fig. 2E . Furthermore, Transwell assays demonstrated that down-regulation of NAC-1 by siNAC1 in DU-145 cells decreased the cell migration abilities compared with NC siRNA (Fig. 2F) . These results revealed that silencing of NAC1 expression inhibited the migration of prostate cancer cells.
Identification of NAC1-regulated genes in prostate cancer cells.
According to the preceding data, we performed a microarray analysis to identify the potential genes regulated by NAC1 in the DU-145 cell line. mRNA expression profiles were determined in DU145 cells transfected with NAC1 or NC siRNA. In total, 291 up-regulated mRNAs and 488 down-regulated mRNAs (with fold change |>2| and P<0.05) were identified consistently in the DU145 cells transfected with siNAC1-1 or siNAC1-2 compared with the NC siRNA-transfected cells (data not shown). The results of a Hierarchical Clustering analysis are shown in Fig. 3A , and the top ten pathways associated with the up-regulated and down-regulated genes are shown in Fig. 3B and C respectively.
To validate the microarray results, qPCR was performed in cells transfected with the two independent NAC1 siRNAs, in order to assess the levels of seven genes identified as being associated with the biological process of cancer development based on the microarray analysis. All genes were validated by both siRNAs (P<0.05). NAC1 knockdown efficiency was verified by RT-qPCR and western blotting (Fig. 3D) . Furthermore, we selected β-actin and PKM2 whose expression was unchanged in the microarray to verify the efficiency by western blotting (data not shown). The results revealed that NAC1 siRNAs did not affect the expression of β-actin and PKM2, but effectively down-regulated NAC1. As shown in Fig. 3E , the seven genes were IFNβ and IL-24, whose transcription was repressed by NAC1, and NFATc1, MMP9, GAB1, VEGFA and S100A9, whose transcription was promoted by NAC1.
NAC1 participates in osteoclastogenesis by negatively regulating IFNβ.
Interestingly, upon further exploration of the microarray data, a GO analysis of biological processes revealed that NAC1 negatively regulates IFNβ (data not shown). A previous study reported that IFNβ has the function of regulating osteoclastogenesis (18) ; therefore, we hypothesized that NAC1 may mediate osteoclastogenesis by negatively regulating IFNβ expression in prostate cancer. To verify this hypothesis, PC-3 cells, which are isolated from a bone metastatic site of prostate cancer, were employed for further study. PC-3 cells were transfected with the two NAC1 siRNAs or NC siRNA and after 24 h were seeded into the upper compartment of a Boyden chamber, while RAW 264.7 cells were cultured in the bottom chamber to allow exchange of secreted factors that generate osteoclasts. When NAC1 was silenced in PC-3 cells (Fig. 4A) , the expression of genes associated with the activation of Table II . Correlation of NAC1 expression with clinicopathologic factors in prostate cancer. osteoclasts (such as RANK and MMP9) was significantly decreased in RAW 264.7 cells, as identified by RT-qPCR and western blot analyses (Fig. 4B) . The mRNA and protein levels of IFNβ were increased in PC-3 cells transfected with NAC1 siRNAs compared with the NC siRNA (Fig. 4C ). Furthermore, the protein level of IFNβ, detected by ELISA, was increased in the co-culture medium in the NAC1 siRNA-transfected group compared with the control group (Fig. 4D ). This series of results confirmed that NAC1 participates in osteoclastogenesis through the negative regulation of IFNβ.
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Discussion
The key findings of the present study were that, as a cancer-associated gene, NAC1 promotes the migration of prostate cancer cells and participates in osteoclastogenesis.
NAC1 is up-regulated at advanced clinical stages of prostate cancer, indicating that it may be useful biomarker for tracking the progression of prostate cancer. At present, the treatment of bone metastasis in patients with prostate cancer is unsatisfactory. As an upstream regulatory gene of osteoclastogenesis, NAC1 may represent a novel potential therapeutic target. The results of previous studies have implicated NAC1 in cell proliferation and survival in certain gynecological tumors, such as ovarian cancer, endometrial cancer, cervical carcinomas and uterine sarcoma (11, 17, 19, 20) . However, interestingly, the results of the colony formation and MTT assays in the present study showed that NAC1 expression had no significant effects on cell proliferation in prostate cancer ( Fig. 2C and D) , which is similar to our previous studies in bladder urothelial carcinoma (In press). However, in the Transwell and wound healing assays (Fig. 2E and F) , NAC1-silencing resulted in a decreased capacity for cell migration in the DU-145 cell line, indicating that NAC1 may be essential for metastasis in prostate cancer. Similarly, NAC1 has been shown to promote cell invasion and motility through FOXQ1 in ovarian cancer (16) . Furthermore, NAC1 participate in multitudinous cancer-associated pathways like autophagy, apoptosis and epithelial mesenchymal transition in different cancer cells (21) (22) (23) , indicating that NAC1 exert (11, 19) , but not in the prostate cancer, where it suppresses migration.
On the basis of comparing the transcripts present in NAC1-knockdown and control DU-145 prostate cancer cells by microarray analysis, we validated a set of target genes whose expression levels depend on NAC1. After NAC1 silencing, IFNβ and IL-24 were up-regulated, and NFATc1, S1009, GAB1, MMP9 and VEGFA were down-regulated (Fig. 3E) . In these genes, IFNβ is particularly interesting, as previous studies have shown that IFNβ can negatively regulate osteoclastogenesis; this mechanism involves the secretion of IFNβ by osteocytes, which then acts on osteoclast precursors and down-regulates the protein level of c-Fos, a key factor in osteoclast formation (20, 24, 25) . Combined with the GO analysis (data not shown), which demonstrated that NAC1 can negatively regulate IFNβ, we hypothesized that NAC1 may participate in osteoclastogenesis by reducing IFNβ secretion. To validate this hypothesis, PC-3 cells isolated from prostate cancer bone metastasis were co-cultured with RAW 264.7 cells. RANK and MMP9, which are associated with the activation of osteoclasts, were down-regulated in RAW 264.7 cells when NAC1 was significantly silenced in PC-3 cells (Fig. 4B ). Furthermore, the protein level of IFNβ was increased in the culture medium of PC-3 cells (Fig. 4D) . This finding is consistent with the supposition that NAC1 may play an important role in promoting osteoclastogenesis.
However, it should be noted that this study was only an in vitro examination. Therefore, further studies in vivo are needed to clarify the relationship between NAC1 and osteoclastogenesis. Moreover, other underlying mechanisms of prostate cancer migration and its downstream target genes must be further explored. For example, VEGFA, the most important factor among the angiogenic cytokines (26) (27) (28) , was identified to be positively regulated by NAC1, suggesting that NAC1 may play an important role in promoting tumor angiogenesis in prostate cancer. Indeed, several NAC1-regulated genes identified in the microarray analysis, including IL-24, GAB1 and S100A9, are also involved in cell motility or invasion (29) (30) (31) .
In conclusion, we have demonstrated that NAC1 promotes the migration of prostate cancer cells, and identified a significant correlation between NAC1 and osteoclastogenesis. 
